natgillin/translations-raw huggingface dataset:
Assembly according to claim 15, further comprising a protrusion projecting in the opposite direction of the casting plate sliding face. 
Ploča u skladu s patentnim zahtjevom 16, naznačena time, da izbočina (30) strši u smjeru suprotnom od klizne površine ploče za lijevanje (19d, 20d).
Just by the combination of wood with materials being different from wood, novel surface patterns and, therewith, a completely new material aesthetic can be created that enlarge the application range of wood veneer. 
Upravo kombinacijom drva s materijalima koji su različiti od drva i s novim površinskim uzorcima može biti stvorena potpuno novi estetski izgled materijala, što proširuje opseg primjene turnira od drva.
The composition according to any one of claims 1 to 8, for its use in the treatment of rheumatoid arthritis (including juvenile rheumatoid arthritis or Still's disease), ankylosing spondylitis, osteoarthritis and other non-rheumatoid (seronegative) arthropathies, non-articular rheumatic conditions, frozen shoulder (capsulitis), bursitis, tendinitis, tenosynovitis, swollen joints, low back pain and other disorders of the muscles, bones and tendons; sprains and strains, dysmenorrhoea, dental and postoperative pain, symptomatic headache including migraine headache, pain and fever in hospitalized patients, pyrexia in children over one year of age, pericarditis and patent ductus arteriosus (Patent ductus arteriosus (PDA), said composition being used with no dilution. 
Pripravak prema bilo kojem od zahtjeva 1 do 8, za njegovu uporabu u liječenju reumatoidnog artritisa (uključujući juvenilni reumatoidni artritis ili Stillovu bolest), ankiloznog spondilitisa, osteoartritisa i drugih ne-reumatoidnih (seronegativnih) artropatija, izvanzglobnih reumatičnih stanja, smrznutog ramena (kapsulitis), burzitisa, tendinitisa, tenosinovitisa, oteklih zglobova, boli u donjem dijelu leđa 1 drugih poremećaja mišića, kostiju i tetiva; iščašenja 1 uganuća, dismenoreje, dentalne i postoperativne boli, simptomatske glavobolje uključujući migrenu, boli i temperature u hospitaliziranih bolesnika, temperature u djece starije od jedne godine, perikarditisa i perzistentnog ductus arteriosus (Patent ductus arteriosus (PDA), taj pripravak se koristi bez razrjeđivanja.
A method according to claim 12, wherein the semiconductor material (317) is a p-type semiconductor material and the another semiconductor material (316) is an n-type semiconductor material. 
Postupak prema zahtjevu 12, naznačen time što poluvodički materijal (317) je p-tip poluvodičkog materijala, a drugi poluvodički materijal (316) je n-tip poluvodičkog materijala.
A molecule according to the use of claim 4, for use in the treatment or prevention of Alzheimer's disease, wherein said Alzheimer's disease is clinical Alzheimer's disease. 
Molekula u skladu s patentnim zahtjevom 4, naznačena time što je namijenjena upotrebi u liječenju ili sprječavanju Alzheimerove bolesti, gdje je navedena Alzheimerova bolest klinički stadij Alzheimerove bolesti.
The antibody for use according to any one of claims 1 to 8, wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor. 
Protutijelo za uporabu u postupku liječenja ili prevencije fibroze prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da je fibroza u bubregu i povezana je s kroničnom bolesti bubrega.
A method according to claim 1, characterized in that the polyolefin layer (5a) is a polyethylene (PE) layer, preferably in the form of a homopolymer or a copolymer of PE. 
Postupak prema zahtjevu 1, zaznačen time, što je sloj (5a) poliolefina polietilenski (PE) sloj, poželjno u obliku homopolimera ili kopolimera PE.
variants thereof having one or more conservative amino acid substitutions. 
njihove varijante s jednom ili više konzervativnih aminokiselinskih supstitucija.
a first airlock at the first end of the loading channel and a second airlock at the second end of the loading channel; and 
kanal (94) za utovar koji ima prvi kraj (98) za primanje posude i drugi kraj (96) susjedan komori za ulaz posude;
The compound of claim 1, wherein R3 is selected from the group consisting of: methyl, methoxyethyl, 4-pyridylmethyl, 3-pyridylmethyl, 2-pyridylmethyl, benzyl, N,N-dimethylaminopropyl, 3-methylisoxazol-5-yl-methyl, and 4-methylpiperazin-1-yl-propyl, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time da R3 je odabran iz skupine koja sadrži: metil, metoksietil, 4-piridilmetil, 3-piridilmetil, 2-piridilmetil, benzil, N,N-dimetilaminopropil, 3-metilizoksazol-5-il-metil, i 4-metilpiperazin-1-il-propil, ili njihovu farmaceutski prihvatljivu sol.
Composition according to claim 25 or 26 suitable for human and/or veterinary use. 
Smjesa prema zahtjevu 25 ili 26, naznačena time, što je pogodna za primjenu kod ljudi i/ili u veterini, t>&
A peptide consisting of a sequence that is selected from the group of SEQ ID No. 4 and SEQ ID No. 5. 
Peptid koji se sastoji od slijeda aminokiselina prema SEQ ID No. 22.
A pharmaceutical composition according to claim 18, further comprising a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav prema zahtjevu 18, naznačen time, da dodatno obuhvaća farmaceutski prihvatljiv razrjeđivač ili nosač.
A mortar comprising a hydraulic binder as claimed in claim 14 . 
17. Žbuka koja sadrži hidraulično vezivo prema patentnom zahtjevu 14.
Inhalers are usually coloured to identify the medicament being delivered and it is useful to make sure that the cap and strap are the same colour. 
Inhalatori su obično obojeni da se označi medikament koji se primjenjuje i korisno je ako zatvarač i vrpca mogu biti jednake boje.
The at least one hydroxyhydrocarbyl residue preferably comprises at least two hydroxyl groups. 
Najmanje jedan hidroksihidrokarbilni ostatak poželjno sadržava najmanje dvije hidroksilne skupine.
wherein the opioid antagonist is present in said extract in a weight percent amount, based on the total amount of opioid antagonist in the dosage form, that is more than 15 %-points less than the weight percent amount of opioid agonist present in the extract, based on the total amount of opioid agonist in the dosage form, and wherein the opioid antagonist is naloxone or a pharmaceutically acceptable salt thereof, and the opioid agonist is selected from pharmaceutically acceptable salts of any of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone. 
€) odvajanje ekstrakta gdje je opioidni antagonist prisutan u ekstraktu u količini u težinskom postotku, na temelju ukupne količine opioidnog antagonista u dozirnom obliku, a to je više od 15%-bodova manje od težinskog postotka opioidnog agonista u ekstraktu, na temelju ukupne količine opioidnog agonista u dozirnom obliku, i gdje je opioidni agonist oksikodon hidroklorid, a opioidni antagonist je nalokson hidroklorid, u dozirnom obliku su prisutni u omjeru količina 2:1.
The compound of Formula XXIII can be deprotected to form a compound of Formula XXIV, which can then be oxidatively cleaved to give a compound of Formula XXV. 
Formula XXII čime se dobiva spoj Formule XXII: b. hidrogeniranje spoja Formule XXII, čime se dobiva spoj Formule XXIII: a. H o
Other preferred embodiments are compounds I: wherein heteroaryl is selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, imidazolyl, oxadiazolyl, thiadiazoyl, pyrazolyl, tetrazolyl and triazolyl; wherein said heteroaryl is independently optionally substituted with one to three same or different halogens or from one to three same or different substituents selected from F; 
Spoj prema zahtjevu 9, naznačen time što: heteroaril se izabire iz skupine koja obuhvaća piridinil, pirazinil, piridazinil, pirimidinil, furanil, tienil, tiazolil, oksazolil, izoksazolil, imidazolil, oksadiazolil, tiadiazoil, pirazolil, tetrazolil i triazolil; gdje je heteroaril nezavisno po izboru supstituiran jednim do tri istih ili različitih halogena ili jednim do tri istih ili različitih supstituenata izabranih između F.
Use according to claim 5, characterized in that the composition is applied on a paper wrapper for smoking article (25) as partial coating (1a), in the form of bands parallel to each other and arranged perpendicularly to the longitudinal axis of the smoking article (10). 
Uporaba u skladu s patentnim zahtjevom 5, naznačena time što se kompozicija nanosi na papirni omotač proizvoda (25) za pušenje kao djelomični premaz (1a), u obliku traka koje su međusobno paralelne i raspoređene na uzdužnu os proizvoda (10) za pušenje.
Another aspect of the invention is a pharmaceutical composition containing the active ingredient (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol in crystalline form and at least one pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži kristalnu modifikaciju (1R,2R)-3-(3-dimetilamino-1-etil-2- metilpropil)fenola prema jednom ili više od zahtjeva 1-4, 6-9 i 12-13 i farmaceutski kompatibilni nosač.
there are also introduced into the mixing reactor 3 predetermined quantities of the reactants that are the sources of microelements, e.g. 
u reakcijsku mješalicu 5 dodaju se odmjerene količine reagenata koji su izvori mikroelemenata npr.
The invention relates to a process for the manufacture of a veneer, to the veneer per se which is produced by means of said process, as well as to a device for carrying out said process. 
Ovaj opis se odnosi na postupak za proizvodnju furnira, na furnir sam za sebe koji se proizvodi pomoću navedenog postupka, kao i na uređaje za izvođenje navedenog postupka.
A method or use as defined above wherein the psychosis or psychotic episode arises from or is associated with schizophrenia. 
* - Uporabu spoja prema gore navedenim uporabama pri čemu su psihoza ili psihotična epizoda potaknuti ili su povezani sa šizofrenijom.
A process according to any one of claims 1 to 8 wherein the reaction mixture under a) is seeded with seeds of the salt of (aS,BR)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-B-phenyl-3-quinolineethanol and the resolution agent as defined in any one of claims 1, 2 or 3 after adding the resolution agent to the reaction mixture. 
Postupak prema bilo kojem od zahtjeva 1 do 8 naznačen time da reakcijska smjesa iz a) je zametnuta sa zametcima soli (aS,BR)-6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-B-fenil-3-kinolinetanola i sa sredstvom za razlučivanje kako je definirano u bilo kojem od zahtjeva 1, 2 ili 3 nakon dodavanja sredstva za razlučivanje u reakcijsku smjesu.
The composition of any one of claims 1-13, wherein the SAP polypeptide was expressed in a CHO cell. 
ekspresija SAP polipeptida u CHO stanici; i ii) izolaciju SAP polipeptida iz stanice.
a mutated Tsp gene encoding a Tsp protein having 50% or less of the protease activity of a wild-type non-mutated Tsp protein as shown in SEQ ID NO: 26 and; 
mutirani Tsp gen koji kodira Tsp protein koji ima 50% ili manje aktivnosti proteaze divljeg tipa ne-mutiranog Tsp proteina kao što je prikazano u SEK ID BR: 26 i;
In a further aspect the invention relates to a method of treating or preventing a disease or disorder involving cells expressing CLD18, preferably CLD18A2, comprising administering to a subject an antibody of the invention, a conjugate thereof with a therapeutic agent, or a pharmaceutical composition comprising the antibody of the invention or the conjugate thereof with a therapeutic agent. 
Protutijelo sukladno patentnom zahtjevu 1, konjugat sukladno patentnom zahtjevu 3 ili farmaceutski pripravak sukladno patentnom zahtjevu 4 za uporabu u postupku liječenja ili prevenciju bolesti ili poremećaja koji uključuje stanice koje eksprimiraju CLD18A2.
A process according to claim 10 wherein the temperature difference is up to 20°C. 
Postupak u skladu s patentnim zahtjevom 10 pri čemu je razlika temperatura do 20*C.
A composition comprising a bacterial strain of the species Eubacterium contortum, for use in a method of treating or preventing an inflammatory or autoimmune disease, or cancer. 
Sastav prema zahtjevu 1, za upotrebu u postupku liječenja ili prevencije inflamatorne ili autoimune bolesti, ili karcinoma.
reacting the compound of Formula IV or salt thereof, with a halogenating agent, to form a compound of Formula VI or salt thereof; wherein X2 is halogen and said halogenating agent is preferably thionyl chloride; and reacting said compound of Formula VI, or salt thereof, with CH3NH2 to form a compound of Formula V or salt thereof. 
VI pri čemu X, je halogen i navedeno sredstvo za halogeniranje je poželjno tionil klorid; i (d) (41) reakciju navedenog spoja s Formulom VI, ili njegove soli, s CHaNH, da se dobije spoj s formulom V ili njegova sol.
It is then concentrated under reduced pressure, quenched with water (5 ml) and extracted with ethyl acetate (2x5 mL). 
To se zatim koncentrira pod sniženim tlakom, ugasi vodom (5 ml), te ekstrahira etil-acetatom (2 x 5 ml).
PP-F11: X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y is norleucine and X is a chemical group attached to the peptide for the purpose of diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. 
X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y -Asp-Phe-NH>, pri čemu Y predstavlja aminokiselinu koja zamjenjuje metionin, i X predstavlja kemijsku skupinu koja je priključena na peptid u svrhu dijagnostičke i/ili terapeutske intervencije kod odgovarajućih bolesti vezanih uz CCK2-receptor.
The exemplified compounds 1-119 of the invention are A2A receptors antagonists having a human AZA binding affinity (Ki) of 530 nM or less. Formulation Examples 
Primjeri spojeva 1 - 119 dani ovim izumom su antagonisti A, receptora, koji imaju afinitet vezanja izražen kao ljudski A2, receptor afinitet vezanja (K;) od 530 nM ili manji.
Low and/or high-density polyethylene 
- polietilen niske i/ili
A polynucleotide encoding the polypeptide of claim 1 or claim 2. 
Polinukleotid koji kodira polipeptid u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2.
Thus, the operating force of the closing mechanism can easily be regulated and adapted to the needs of a user of the device. 
Uređaj u skladu s patentnim zahtjevom 3, naznačen time što se može namjestiti sila napinjanja mehanizma za zatvaranje.
The electricity supply control system according to claim 1, wherein the control unit is further configured to connect one of the at least two electric meters and disconnect the other electric meters at any given moment in time, based on said real-time data and at least one predefined condition. 
Sustav za kontrolu električnog napajanja (100) u skladu s patentnim zahtjevom 1, naznačen time što je kontrolna jedinica (105) dodatno tako konfigurirana da spoji jedno od najmanje dva brojila električne energije (103), a otpoji druga brojila električne energije u bilo kojem trenutku vremena, na osnovi navedenih podataka u stvarnom vremenu i najmanje jednog zadanog uvjeta.
is selected from: wherein * indicates the bond to the (CH2)n group in formula (I). 
* označuje vezu na skupinu (CH>), u formuli (1).
Sulfonylureas are a widely prescribed class of oral medications for the treatment of diabetes. 
(54) Naziv izuma: UPORABA PASIREOTIDA ZA LIJEČENJE ENDOGENE HIPERINZULINEMIJSKE
The outside wall with an extrusion ridge or without one is double. 
Vanjski zid sa prijelomom u obliku izbočenja ili bez prijeloma je dvostruki.
US 5,344,932 discloses glutamic acid derivatives of the formula: wherein R5 is H or NH2, R4 is H or OMe, and R2 is H or a pharmaceutically acceptable cation, and discloses that they have an inhibitory effect on one or more enzymes which utilise folic acid and its metabolic derivatives as a substrate. 
US 5,344,932 donosi derivate glutaminske kiseline formule: gdje R' je H ili NH2, R* je H ili OMe, i R? je H ili farmaceutski prihvatljiv kation, i otkriva da oni imaju inhibitorski učinak na jedan ili više enzima koji kao supstrat koriste folnu kiselinu i njene metaboličke derivate..
A vector comprising the nucleic acid molecule of claim 8. A host cell comprising the vector of claim 9. 
Vektor, naznačen time, da sadrži molekulu nukleinske kiseline prema zahtjevu 5.
a ceramic spool having a longitudinal axis; 
keramički valjak (2) koji ima uzdužnu os;
7B). In various embodiments, genetically modified mouse comprise a knockout of the endogenous mouse λ light chain locus. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što endogeni lokus imunoglobulina lakog lanca 2 sadrži endogeni mišji pojačivač 2.4 ili endogeni mišji 3' pojačivač.
Compounds of general formula (I) in which X represents CR3 or N, wherein R3 represents H; C1-10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; 
Spojevi opće formule (I) [image] naznačeni time da X predstavlja CR3 ili N, pri čemu R3 predstavlja H; C1-10 alkil, zasićen ili nezasićen, razgranat ili nerazgranat, nesupstituiran ili mono- ili polisupstituiran;
Compound I according to claim 4, wherein said HBr addition salt is characterised by an XRPD as depicted in figure 1. 
Spoj za uporabu prema zahtjevu 3, taj spoj je naznačen XRPD-om kako je prikazano na slici 1.
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:117 and/or a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:116; 
(e) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 117i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 116;
providing a composition containing a cosmetically effective amount of NGF of 10-8% to 5% by weight of the total weight of the composition; 
uzimanje pripravka koji sadrži kozmetički aktivnu količinu faktora rasta živčanih stanica (engl. nerve cell growth factor, NGF) od 10-8% do 5% ukupne težine pripravka;
In a preferred embodiment, each region (6a, 6b) contains means (7) for venting, most preferably a venting port, which also functions as a stop flow valve. 
Mikrofluidički uređaj u skladu s patentnim zahtjevom 4, naznačen time što navedeni dio za odzračivanje se sastoji od otvora za odzračivanje (7), koji djeluje kao kao ventil za zatvaranje protoka.
In this regard, the shape and size are adapted to match the applicable conditions of use. 
S obzirom na to, oblik i veličina se prilagođavaju tako da se usklade s uvjetima primjene pri upotrebi.
attaching an isosubstrate of the isoprenoid transferase to an active agent; and 
vezanje izosupstrata izoprenoid transferaze na aktivno sredstvo; i
The length of the core 1 can be variable, according to requirements. 
Prema zahtjevima, dužina jezgre 1, može biti različita.
ring A is an optionally substituted 5-6 member monocyclic aryl or monocyclic heteroaryl; 
[image] gdje prsten A je izborno supstituiran 5-6 –člani monociklični aril ili monociklični heteroaril;
A nucleic acid, encoding a peptide according to any one of Claims 1 to 4, or an expression vector expressing said nucleic acid. 
Metoda u skladu s patentnim zahtjevom 9, pri čemu stanica koja prezentira antigen sadrži vektor ekspresije koji eksprimira navedeni peptid u skladu sa zahtjevom 1 ili 2.
A compound according to claim 19 having the formula (IV): wherein z is 0, 1 or 2, R20 is selected from hydrogen, methyl, hydroxy and fluorine, provided that when z is 0, R20 is other than hydroxy. 
RLZN OR N-N 3 (TV) gdje z je 0, 1 ili 2, R" je izabran između vodika, metila, hidroksi i fluora, uz uvjet da kada je z jednako 0, R* nije hidroksi.
According to one embodiment of the present invention, the at least one dissolved and/or colloidal substance is/are a) originated from wood and/or wood resins, preferably selected from the group comprising polysaccharides, such as hemicelluloses, lignin, starch and pectins, resin acids, fats, fatty acids, fatty alcohols, terpenes, terpenoids, polyisoprenes, sterols, steryl esters, waxes and mixtures thereof, and/or b) originated from paper coatings, coating binders, printing inks, de-inking chemicals, hot melts and/or adhesives. 
Upotreba u skladu s patentnim zahtjevom 10, naznačena time što se najmanje jedan otopljeni i/ili koloidni materijal a) dobiva iz drva i/ili drvnih smola, koje se po mogućnosti bira iz skupine koju čine polisaharidi, poput hemiceluloza, lignin, škrob i pektini, smolne kiseline, masti, masne kiseline, masni alkoholi, terpeni, terpenoidi, poliizopreni, steroli, sterilni esteri, voskovi i njihove smjese, i/ili b) dobiva iz papirnih premaza, veziva za premaze, tiskarskih tinta, kemikalija za uklanjanje tinte, vrućih talina i/ili ljepila.
the testing set of videos is prepared by selecting some videos of the plurality of videos, and classifying the selected videos in a random order for visualization, wherein the score of each of the videos is not to be displayed with the corresponding video, and wherein the selection and/or classification of the videos is different from the training set of videos. 
HR P20181404 T1 - komplet videozapisa za testiranje se priprema odabirom nekih videozapisa iz mnoštva videozapisa, i klasificiranjem odabranih videozapisa po nasumičnom redu za vizualizaciju, gdje rezultat svakog videozapisa ne smije biti prikazan s odgovarajućim videozapisom, i gdje su odabir i/ili klasifikacija videozapisa različiti od onih kod kompleta videozapisa za obuku.
A mite composition comprising at least one rearing population of a predator mite species of the family Phytoseiidae and a first food source for this predator mite species, wherein the rearing population of the predator mite species and the first food source are both located in a common housing, which has at least one opening which allows individuals of the predator mite species to leave the common housing, wherein the mite composition comprises a second food source for the predator mite species, characterized in that the second food source is at least one rearing population of a mite species belonging to the Astigmata, wherein the second food source is located outside the common housing and preferably spaced apart with respect to the common housing. 
Sustav koji ima najmanje jednu rasplodnu populaciju grabežljive vrste grinja iz porodice Phytoseiidae i prvi izvor hrane za ovu grabežljivu vrstu grinja, pri čemu su rasplodna populacija grabežljive vrste grinja i prvi izvor hrane smješteni u zajedničko kućište, koje ima najmanje jedan otvor koji omogućava pojedincima grabežljive vrste da napuste zajedničko kućište i drugi izvor hrane za grabežljive vrste grinja, naznačen time, da je drugi izvor hrane najmanje jedna rasplodna populacija vrste grinja koje pripadaju redu Astigmata i drugi izvor hrane se nalazi izvan zajedničkog kućišta. Sustav u skladu s patentnim zahtjevom 9, naznačen time, da drugi izvor hrane je udaljen od zajedničkog kućišta.
A method of stimulating an immune response in a subject, comprising introducing a compound as defined in claim 1, or a composition comprising said compound, and an antigenic molecule to be internalized, into one or more cells in vitro, in vivo or ex vivo by a method comprising contacting said cells with said compound and said antigenic molecule to be introduced, and irradiating the cells with light of a wavelength effective to activate the photosensitising agent of the compound thereby releasing said antigenic molecule to be introduced into the cytosol and presenting the antigenic molecule or a part thereof of sufficient size to stimulate an immune response, and where necessary administering said cells to said patient, whereby an immune response is stimulated in said subject. 
Spoj ili pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5 ili 9, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju bolesti, poremećaja ili infekcije kod subjekta generiranjem imunosnog odgovora, po mogućnosti postupkom cijepljenja, gdje se po mogućnosti navedeno liječenje ili sprječavanje sastoji u stavljanju u kontakt stanica subjekta s navedenim spojem ili pripravkom, te ozračivanju stanica svjetlom valne duljine koja djelotvorno aktivira fotosenzibilizirajuće sredstvo spoja, gdje se navedenu antigensku molekulu otpušta u citosol stanice, a antigensku molekulu ili njezin dio dovoljno velik za stimuliranje imunosnog odgovora se predočava na površini stanica.